• Skip to main content
  • Skip to main content
Choose which site to search.
University of Arkansas for Medical Sciences Logo University of Arkansas for Medical Sciences
Psychiatric Research Institute
  • UAMS Health
  • Jobs
  • Giving
  • Clinical Care
    • AR ConnectNow
      • Frequently Asked Questions
      • Mental Health Resources
      • Substance Abuse Facilities
      • Contact AR ConnectNow
    • Center for Trauma Prevention, Recovery and Innovation
      • About Us
        • Collaborations
        • Our Team
      • In The Media
      • Resources
      • Training & Education
        • Education For The Public
        • Training For Professionals
      • What Is Trauma?
    • Child Study Center
      • Dialectical Behavior Therapy
      • Family Resources
        • Handouts for Parents
        • Books
        • Videos
      • Meet the Team
      • Treatment and Services
    • Interventional Psychiatry
      • Electroconvulsive Therapy
      • Esketamine
      • Ketamine Infusions
    • Neurodiversity Clinic
    • Northwest Arkansas Crisis Stabilization Unit
    • STRIVE
    • The Couples Center
      • Helping Couples Expand Their Love Capacities
      • Interdynamic Couples Therapy
      • SOS for Cabin Fever Couples
      • The Essentials of Sex Therapy
      • 2023 Training Opportunities and Certification Program with Chelsea Wakefield, Ph.D., LCSW
      • 2023 Training Schedule
    • Walker Family Clinic
      • Mental Health Resources
    • Women’s Mental Health Program
    • Center for Addiction Services and Treatment (CAST)
      • Improving Access To Treatment For Opioid Use Disorder
      • MATRIARC
        • Project ECHO
      • Medication and Counseling Treatment
      • Medications To Treat Opioid Use Disorders
      • Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
      • Suboxone Treatment Program
      • Subutex Treatment Program
      • What is Buprenorphine?
      • What Is Methadone?
      • What Is Naltrexone?
      • What Is Vivitrol?
      • Drugs and Addiction
      • Opioid Use Disorder
    • Inpatient Units
      • Child Diagnostic Unit
        • Child Diagnostic Unit Videos
      • Women’s Inpatient Unit – 5 North
    • Pulaski County Regional Crisis Stabilization Unit
      • Operation SAVE
    • Neuropsychology
    • Psychiatry Clinic in Fayetteville
  • Education
    • For Current Residents
  • Research
    • Center for Addiction Research
      • Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
      • What is Vivitrol?
      • Faculty
        • Alison Oliveto, Ph.D
        • Linda Larson-Prior, Ph.D.
        • Merideth Addicott, Ph.D.
        • Michael Mancino, M.D.
        • Nihit Kumar, M.D.
    • Center for Health Services Research
      • Behavioral Health QUERI
      • Health Services Research and Development Service
      • Rural Outreach Program
        • Rural Outreach Program Team
      • South Central (VISN 16) Mental Illness Research, Education and Clinical Center
      • Center for Health Services Research Faculty and Staff
        • Brandon J. Griffin, Ph.D.
        • Carolyn J. Greene, Ph.D.
        • Christopher Long, Ph.D.
        • Corey Hayes, Pharm.D., Ph.D., MPH
        • Eva Woodward, Ph.D.
        • Jacob Painter, Pharm.D, Ph.D.
        • Leah Tobey, PT, DPT, MBA
        • Marcela Weber, Ph.D.
        • Mary J. Bollinger, MPH, Ph.D.
        • Melissa J. Zielinski, Ph.D.
        • Michael Cucciare, Ph.D.
        • Michael Wilson, M.D., Ph.D., FAAEM, FACEP
        • Prasad R. Padala, M.D., M.S., FACHE
        • Rajinder “Sonia” Singh, Ph.D.
        • Sara J. Landes, Ph.D.
        • Traci Abraham, Ph.D.
        • Angie Waliski, Ph.D.
        • Ellen P. Fischer, Ph.D.
        • Geoffrey M. Curran, Ph.D.
        • Greer Sullivan, M.D., M.S.P.H.
        • Jeffrey M. Pyne, M.D.
        • JoAnn Kirchner, M.D.
        • Joy Reeves Pemberton, Ph.D.
        • Karen Drummond, Ph.D.
        • Kristen M. Viverito, Psy.D.
        • Puru Thapa, M.D., M.P.H.
        • Richard R. Owen, M.D.
        • Teresa Hudson, Pharm.D., Ph.D.
        • Teresa L. Kramer, Ph.D.
      • Postdoctoral Fellowship
        • CeMHOR/HSR&D
        • MIRECC
    • Health and the Legal System (HEALS) Lab
      • Projects in the Health and the Legal System (HEALS) Lab
    • Helen L. Porter and James T. Dyke Brain Imaging Research Center
      • Childhood Trauma Study
      • Directions to BIRC
      • Events
      • MRI Frequently Asked Questions
      • Prospective Collaborators
      • Prospective Participants
      • Prospective Trainees
      • Publications
      • Media
      • Resources
    • Neurocognitive Dynamics Laboratory
      • Current Studies
    • Neurodevelopmental Risk and Resilience Program
    • Research Trials
  • Patients and Visitors
    • Advisory Board
    • Art of the Psychiatric Research Institute
    • Mental Health Resources
    • Mission And Vision Statements
    • Positions at the Psychiatric Research Institute
    • Map and Directions
    • Faculty and Staff
    • Giving
  1. University of Arkansas for Medical Sciences
  2. Psychiatric Research Institute
  3. Research
  4. Center for Addiction Research
  5. Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

The goal of this Center for Addiction Research study is to determine which medication approaches work best for people with opioid use disorder. Opioids include fentanyl, heroin, and prescription pain relievers (e.g., hydrocodone (Vicodin®, Norco®, Lortab®), oxycodone (OxyContin®, Percocet®,), hydromorphone (Dilaudid® etc).The participant may choose one of two study drugs – Buprenorphine or VivitrolTM. Buprenorphine is used to treat people with opioid problems by managing opioid withdrawal symptoms. Vivitrol is used to help people, who have successfully stopped taking any opioids, remain abstinent.

If the participant selects Buprenorphine, the participant must agree to be randomly assigned to one of three conditions: 16mg/day of sublingual Buprenorphine (Suboxone®), 32mg/day of sublingual Buprenorphine (Suboxone®), or monthly XR- Buprenorphine injections. If the participant selects, VivitrolTM, they will need to show that they have not recently used opioids or have had one shot of VivitrolTM in the past month before receiving monthly VivitrolTM injections.

Related Flyers

Click on the links to download the flyer.

  • Newly seeking treatment for heroin or other opioids?

  • Are you in recovery from opioid addiction?

  • UAMS study seeking participants wanting help staying off opioids

Half of participants will randomly be chosen to receive a phone app, Pear-002a. This app may be used to help track and manage cravings. Study participants will be expected to stay on study medication, meet with a study doctor for medication management, and communicate with research staff for up to 1.5 years, with more follow-up interviews with research staff periodically for another 6 months. There is no cost to participate in this study. Research subjects who are found eligible will receive monetary compensation for their time.

Eligibility Criteria:

  • Ages 18+
  • Problem with opioids (heroin, fentanyl, prescription pain killers)

This study is currently accepting participants. For more information, call 501-526-7969.  All calls are confidential.

Psychiatric Research Institute LogoPsychiatric Research InstitutePsychiatric Research Institute
Mailing Address: 4224 Shuffield Drive, Little Rock, AR 72205
Phone: (501) 526-8100
  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Pinterest
  • Disclaimer
  • Terms of Use
  • Privacy Statement

© 2023 University of Arkansas for Medical Sciences